Britannia Announces Listing to the Frankfurt Stock Exchange

Toronto, Ontario–(Newsfile Corp. – March 7, 2022) – Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company“) is pleased to announce that its common shares (“Shares“) have been accepted for listing on the Frankfurt Stock Exchange (“FSE“). The Shares will currently trade under the symbol “L020” (L-Zero-Two-Zero). Regulatory filings and additional information regarding Britannia are available on SEDAR at www.sedar.com.

The listing of Britannia shares on the FSE represents the first step in the Company’s capital markets strategy to improve access and awareness of the Company’s shares to global investors, in particular in the UK and Europe where the bulk of Britannia’s operations are based.

Peter Shippen, Britannia’s CEO, comments:

“We are pleased to be listed on to the Frankfurt Stock Exchange and trade in Europe where many of our larger competitors command significantly higher trading multiples. As Britannia continues to build out our global product platform and expand our services in new areas, we feel it is important that UK and European investors can confidently and efficiently trade our shares and participate in Britannia’s growth.”

About Britannia Life Sciences Inc.

Britannia Life Sciences Inc. is a global platform offering an integrated suite of services to assist companies along their product development journey. Britannia’s services, including product formulations, safety assessments, analytical and microbiological testing, global compliance and consumer evaluations are offered to companies ranging from multinationals to start-ups particularly in the cosmetics, food and wellness industries. Britannia has garnered significant expertise in the development and regulatory approval of topical and edible cannabis products, including preparation and support for novel food authorizations.

Britannia’s head office is located at 120 Adelaide Street West, Suite 2400, Toronto, Ontario, M5H 1T1.

For further information contact:
Britannia Life Sciences Inc.
Email: investors@britannia.life

Forward Looking Information

This press release may contain certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Britannia and its business. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected” “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”. “estimates”, “believes” or intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Except as required by law, Britannia assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. The reader is cautioned not to place undue reliance on forward-looking statements.

For a detailed description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s filings statement available on SEDAR under the Company’s profile at www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115802